Clinical trial
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Efficacy, Safety, and Durability of a Single Intravitreal Injection of 4D-150 Versus Aflibercept in Adults With Diabetic Macular Edema (4SIGHT)
NCT07867080 is registered in ClinicalTrials.gov with 4D Molecular Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Efficacy, Safety, and Durability of a Single Intravitreal Injection of 4D-150 Versus Aflibercept in Adults With Diabetic Macular Edema (4SIGHT)
- Lead sponsor
- 4D Molecular Therapeutics
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 18, 2026
- Completion date
- January 31, 2030
- Enrollment
- 514 (estimated)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic macular edema (dme)